This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Atherosclerosis Market

Atherosclerosis Treatment to gain traction amid rising Cardiac Ailment Incidences and associated co-morbidities

Atherosclerosis Market by Therapy, Surgery, Distribution Channel & Region - Forecast 2022 – 2032

Atherosclerosis Market Snapshot (2022-2032)

[301 Pages Report] The atherosclerosis market is anticipated to attain a valuation of US$ 58,236.4 Million by 2032, growing at a CAGR of 2.8% between 2022 and 2032, from a current value of US$ 44,183.8 Million in 2022. The rise in the prevalence of cardiovascular disorders is a significant factor driving market growth.

Data Points

Key Statistics

Expected Market Value (2022)

US$ 44,183.8 Million

Anticipated Forecast Value (2032)

US$ 58,236.4 Million

Projected Growth Rate (2022-2032)

2.8% CAGR

Atherosclerosis is the shrinking of a vein caused by plaque accumulation. Atherosclerosis is a kind of arteriosclerosis (stiffening or solidifying of the artery walls). The sickness disrupts the flow of blood throughout the body, posing significant cardiovascular complications.

Atherosclerosis starts when the endothelium is damaged, allowing LDL cholesterol to accumulate in the arterial wall. To clean up the cholesterol, the body sends macrophage white platelets.

However, the cells occasionally halt at the impacted spot. After a while, this resulted in the formation of plaque, which was composed of bad cholesterol (LDL cholesterol) and macrophage white platelets. The plaque obstructs the corridor, disrupting the flow of blood throughout the body. This may result in blood clusters, which can lead to life-threatening diseases such as heart attack, stroke, and other cardiovascular disorders.

Aside from age, the following factors increase the risk of atherosclerosis: high blood pressure, high cholesterol, diabetes, obesity, smoking or other tobacco use, family history of early heart disease, lack of exercise, and a poor diet.

Atherosclerosis Demand Analysis (2017 To 2021) Vs Market Outlook (2022 To 2032)

The global demand for atherosclerosis treatment is projected to increase at a CAGR of 2.8% during the forecast period between 2022 and 2032, reaching a total of US$ 58,236.4 Million in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 1.9%.

The rising number of heart attacks caused by atherosclerosis or coronary heart disease is expected to drive up demand for atherosclerosis treatment products. The ageing population is expected to drive demand during the forecast period.

According to the CDC (Centres for Disease Control and Prevention), coronary illness accounts for approximately 610,000 deaths per year in the United States, accounting for roughly one out of every four reported deaths. Coronary disease is the most well-known type of coronary disease, killing over 370,000 people each year.

This increase in the baby boomer population is expected to increase the number of atherosclerosis patients and, as a result, demand for treatment over the forecast period.

The market for atherosclerosis is growing due to increased prevalence, obesity, sedentary lifestyle, hypertension, dyslipidemia, particularly a decrease in high thickness cholesterol (HDL-C), and elevated cholesterol slim down.

Statins, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers (BB), antiplatelets, calcium channel blockers (CCBs), and nitrates are among the medications used to treat atherosclerosis.  

Yosprala (headache medicine and omeprazole), Praluent (alirocumab), Dalcetrapib (RG1658), Vorapaxar (SCH 530348), Canakinumab (ACZ885), Varespladib (A 002), Aliskiren, Generx, Xarelto (rivaroxaban), Anacetrapib (MK0859), and others are expected to be launched during the forecasting period.

Which Are Some Prominent Drivers Of Atherosclerosis Market?

An Expanding Geriatric Population base and Subsequent Rise in Cardiac Anomalies

The worldwide atherosclerosis industry is poised to increase as the geriatric population grows and the incidence rate of heart attacks caused by coronary heart disease or atherosclerosis rises. Furthermore, the availability of new treatment approaches (both branded and generic) is a major driver of the global atherosclerosis therapeutics market.

According to the Centres for Disease Control and Prevention (CDC), approximately 610, 000 people in the United States died as a result of heart disease, accounting for nearly one out of every four deaths. Coronary artery disease is the most common type of heart disease, accounting for approximately 370,000 deaths each year. These factors are expected to boost the global market for atherosclerosis.

Increasing Prevalence of Obesity and High Cholesterol to Widen Growth Prospects

Rising obesity and high cholesterol rates are expected to boost market growth by increasing the risk of atherosclerosis. According to the World Health Organization, approximately 40 million children under the age of five were overweight or obese in 2018. (WHO).

Increased consumption of high-fat, high-sugar foods, as well as an increase in physical immobility as a result of the increasingly inactive nature of many types of work, changing modes of transportation, and increasing urbanisation, are all contributing to high cholesterol rates, resulting in rapid market growth.

Furthermore, rising awareness-raising initiatives by public and private organisations will expand the atherosclerosis market. Furthermore, the sedentary lifestyle of people, such as high alcohol consumption and smoking addiction, will result in the expansion of the atherosclerosis market. The rising level of disposable income and the high prevalence of high blood pressure are expected to drive the industry's growth rate during the forecast period.

What Are The Challenges Faced By The Atherosclerosis Market?

Absence of Definitive Therapy to Stymie the Market Growth

New competitors in the atherosclerosis market have demonstrated increased adequacy and security profiles, as well as a reduction in CHD risk factors. Atherosclerosis, also known as coronary artery disease, has two treatment options: coronary artery bypass grafting (CABG) and angioplasty.

The CAD death rate is relatively high when compared to other diseases caused by coronary events associated with CAD, such as myocardial infections (MI), angina, and strokes. As a result, the antidote to such situations remains an unexplored area of research and development for pharmaceutical companies seeking to bring breakthrough drugs to market.

However, the absence of definitive therapy, side effects and limited efficacy of current medications, and reliance on symptom-based treatment in certain situations are likely to stymie revenue growth in the atherosclerosis market throughout the forecast period.

Moreover, the high cost of the treatment will stymie the market's growth rate. The atherosclerosis market will be challenged by a lack of skilled professionals and a dearth of healthcare infrastructure in developing economies. Furthermore, strict regulatory policies and a lack of public awareness will restrain and impede market growth during the forecast period.

Region-Wise Insights

How is the North American Atherosclerosis Market Shaping Up?

High Prevalence of Cardiovascular Diseases Creating Opportunities for Atherosclerosis Treatment Providers

The North American atherosclerosis market is slated to acquire a market share of 37% in 2022. The presence of key players, the high prevalence of cardiovascular diseases and atherosclerosis, and established healthcare infrastructure are some of the key factors responsible for the market's large share. Furthermore, beneficial government initiatives and an increase in the number of research collaborations are expected to drive market growth.

Because of supportive healthcare policies, a large number of patients, and a developed healthcare market, the United States have the largest share in this region. Every year, approximately 647,000 Americans die from heart disease, accounting for one in every four deaths.

Every year, the United States spends approximately US$ 219 billion on heart disease. According to statistics, the increasing patient pool and disposable revenue in this country drive regional market growth.

Why is Asia-Pacific considering the Fastest Growing Market for Atherosclerosis?

Increasing Geriatric Population favouring market growth

Asia-Pacific is anticipated to increase during the forecast period of 2022-2032 due to an increasing geriatric population and rising disposable income levels in this region.

Furthermore, the expansion of healthcare infrastructure and rising government initiatives will accelerate the market's growth rate in this region. Thus, Asia-Pacific is expected to hold 25% of market share for Atherosclerosis market in the forecast period 2022-2032.

Category-Wise Insights

Which Therapy Segment is Gaining Traction in the Atherosclerosis Market?

Cholesterol-Lowering Medications to remain most sought after

Statins and fibrates are examples of cholesterol-lowering medications. The segment's dominance is attributed to the rising prevalence of cardiovascular disease, high cholesterol, and obesity worldwide. According to the World Health Organization, 40 million children under the age of five were overweight or obese in 2018.

A higher intake of energy-dense foods high in fat and sugars, as well as an increase in physical immobility due to the increasingly inactive nature of many types of work, changing modes of transportation, and increasing urbanisation, are factors driving high cholesterol rates and, ultimately, boosting segment growth.

In addition, the approval of new cholesterol-lowering medicines is boosting segment growth. For example, the drugs alirocumab (Praluent) and evolocumab (Repatha) belong to a new class of drugs known as PCSK9 inhibitors, which reduce harmful LDL cholesterol levels by more than 50%. Novel treatment drugs of this type boost segment growth. The growing patient pool and increased approvals of new drugs boost segment growth.

Which Is The Leading Distribution Channel Of Atherosclerosis Market?

Retail Pharmacies Will Continue To Be a Beneficial Distribution Channel

As per Future Market Insights (FMI), the Retail pharmacies segment will become the primary point-of-sale channel for atherosclerosis as they expand to even the most remote locations, making it easier for consumers to present prescriptions and purchase drugs.

Furthermore, retail pharmacists provide more consultative services regarding drug administration routes and potential side effects. Retail pharmacies carry a variety of brands, making them a good place for patients to shop. Hospital pharmacists, on the other hand, operate in a more clinic-oriented manner, having frequent contact with doctors and nurses, and they manage their inventories with only specific brands.

Start-Ups for Atherosclerosis Market

Key startup players in the atherosclerosis market:

  • Moderna is a leader in the development of a new class of drugs based on messenger RNA (mRNA). This novel drug platform is based on the discovery that modified mRNA can direct the body's cellular machinery to produce nearly any protein of interest, ranging from native proteins to antibodies and completely novel protein constructs with therapeutic activity both inside and outside of cells.
  • Humacyte creates novel human tissue-based investigational products for regenerative medicine and vascular surgery. The company's proprietary technology platform is used to isolate and grow stable, "off-the-shelf" investigational human tissue replacements that, if approved, could be tailored to pre-designed clinical and commercial specifications.
  • CardioDx is a Redwood City, California-based cardiovascular genomic diagnostics company. CardioDx creates clinically validated genomic tests to aid in the assessment and tailoring of care for people suffering from cardiovascular disease such as coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
  • Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for patients with high-risk cardiovascular disease.
  • Avinger creates precision medical device technology to combat Peripheral Artery Disease and assist patients in keeping their legs.
  • Milestone Pharmaceuticals is a pharmaceutical company that develops small molecule therapeutics for the treatment of cardiovascular diseases.
  • MyoKardia is a precision medicine company that is discovering, developing, and commercializing targeted therapies for the treatment of serious and underserved rare cardiovascular diseases. Our initial focus is on treating heritable cardiomyopathies, a rare, genetically-driven form of heart failure.
  • On the basis of their proprietary AFFITOME technology, AFFiRiS develops first-in-class antigen specific immunotherapies for the prevention and treatment of chronic illnesses. We believe that active immunization can play a significant role in the prevention and treatment of chronic civilization illnesses such as atherosclerosis, diabetes, and neurodegenerative diseases.
  • Flow MedTech is a Health Wildcatters portfolio company that is developing an innovative therapy to reduce the risk of stroke in atrial fibrillation patients by preventing clot formation in the left atrial appendage. The company's goal is to design, develop, and commercialize novel catheter-based devices to reduce the risk of stroke.

Market Competition

The market for atherosclerosis is moderately competitive, with several major players. Some of the companies that are currently dominating the market are as follows GlaxoSmithKline Plc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Isis, Pharmaceuticals, Inc., Anthera Pharmaceuticals, Novartis AG, Sanofi, Johnson and Johnson, Bayer AG, The Medicine Company and Cardium Therapeutics   are some prominent players.

Recent Developments In The Atherosclerosis Market Are

  • In August 2022,  AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that the European Commission (EC) has approved LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm) and HER2-negative high-risk early breast cancer who have previously received neoadjuvant or adjuvant chemotherapy.
  • In July 2022, GSK plc announced that its wholly owned subsidiary, GSK Finance (No.3) plc, will repurchase all of its outstanding Exchangeable Senior Notes due 2023 for cash.
  • In June 2022, Novartis announced new data from the Phase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension demonstrating that continuous Kesimpta® (ofatumumab) treatment significantly increased the odds of achieving no evidence of disease activity (NEDA-3) versus switching from teriflunomide. These findings were presented at the European Academy of Neurology (EAN) Annual Meeting, which will be held virtually on June 25-28, 2022, in Vienna, Austria.

Report Scope

Report Attribute

Details

Market Value in 2022

US$ 44,183.8 Million

Market Value in 2032

US$ 58,236.4 Million

Growth Rate

CAGR of 2.8% from 2022 to 2032

Base Year for Estimation

2021

Historical Data

2016-2021

Forecast Period

2022-2032

Quantitative Units

Revenue in US$ Million and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Therapy
  • Surgery
  • Distribution Channel
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa 

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • GCC
  • South Africa
  • Israel

Key Companies Profiled

  • GlaxoSmithKline plc.
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Isis Pharmaceuticals, Inc.
  • Anthera Pharmaceuticals
  • Novartis AG
  • Sanofi
  • Johnson and Johnson
  • Bayer AG
  • The Medicine Company
  • Cardium Therapeutics  

Customization

Available Upon Request

Key Segments Profiled In The Atherosclerosis Industry Survey

Atherosclerosis Market by Therapy:

  • Atherosclerosis Medications
  • Cholesterol-lowering Medications
  • Antiplatelet drugs and Anticoagulants
  • Atherosclerosis Beta Blockers
  • Diuretics or Water Pills
  • Angiotensin Converting Enzyme (Ace) Inhibitors
  • Other Atherosclerosis Treatment Therapies

Atherosclerosis Market by Surgery:

  • Atherosclerosis Treatment through Bypass Surgery (Coronary Artery Bypass Grafting (CABG))
  • Atherosclerosis Treatment through Angioplasty
  • Atherosclerosis Treatment through Atherectomy

Atherosclerosis Market by Distribution Channel:

  • Atherosclerosis Treatment in Hospitals
  • Atherosclerosis Treatment via Pharmacies
  • Atherosclerosis Treatment via Drug Stores
  • Atherosclerosis Treatment via Retail Pharmacies
  • Atherosclerosis Treatment in Clinics

Atherosclerosis Market by Region:

  • North America Atherosclerosis Market
  • Latin America Atherosclerosis Market
  • Europe Atherosclerosis Market
  • Asia Pacific Atherosclerosis Market
  • Middle East and Africa Atherosclerosis Market

Frequently Asked Questions

FMI projects the global atherosclerosis market to expand at a 2.8% value CAGR by 2032

The global atherosclerosis market is estimated at a market value of US$ 44,183.8 Million

The global atherosclerosis market is expected to garner a market value of US$ 58,236.4 Million

North America is expected to possess 37.0% market share for Atherosclerosis market in the assessment period 2022-2032

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2016-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2016-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Therapy

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Therapy, 2016-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Therapy, 2022-2032

        5.3.1. Medications

        5.3.2. Cholesterol-lowering Medications

        5.3.3. Antiplatelet Drugs & Anticoagulants

        5.3.4. Beta Blockers

        5.3.5. Diuretics or Water Pills

        5.3.6. Angiotensin Converting Enzyme (ACE) Inhibitors

        5.3.7. Others

    5.4. Y-o-Y Growth Trend Analysis By Therapy, 2016-2021

    5.5. Absolute $ Opportunity Analysis By Therapy, 2022-2032

6. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Surgery

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Surgery, 2016-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Surgery, 2022-2032

        6.3.1. Bypass Surgery (Coronary Artery Bypass Grafting (CABG))

        6.3.2. Angioplasty

        6.3.3. Atherectomy

    6.4. Y-o-Y Growth Trend Analysis By Surgery, 2016-2021

    6.5. Absolute $ Opportunity Analysis By Surgery, 2022-2032

7. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2016-2021

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032

        7.3.1. Hospital Pharmacies

        7.3.2. Drug Stores

        7.3.3. Retail Pharmacies

        7.3.4. Clinics

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2016-2021

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032

8. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2016-2021

    8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        9.2.1. By Country

            9.2.1.1. US

            9.2.1.2. Canada

        9.2.2. By Therapy

        9.2.3. By Surgery

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Therapy

        9.3.3. By Surgery

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Therapy

        10.2.3. By Surgery

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Therapy

        10.3.3. By Surgery

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. U.K.

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Therapy

        11.2.3. By Surgery

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Therapy

        11.3.3. By Surgery

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. Asia Pacific Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

            12.2.1.4. Rest of Asia Pacific

        12.2.2. By Therapy

        12.2.3. By Surgery

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Therapy

        12.3.3. By Surgery

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. MEA Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MEA

        13.2.2. By Therapy

        13.2.3. By Surgery

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Therapy

        13.3.3. By Surgery

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. Key Countries Market Analysis

    14.1. US

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2021

            14.1.2.1. By Therapy

            14.1.2.2. By Surgery

            14.1.2.3. By Distribution Channel

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2021

            14.2.2.1. By Therapy

            14.2.2.2. By Surgery

            14.2.2.3. By Distribution Channel

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2021

            14.3.2.1. By Therapy

            14.3.2.2. By Surgery

            14.3.2.3. By Distribution Channel

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2021

            14.4.2.1. By Therapy

            14.4.2.2. By Surgery

            14.4.2.3. By Distribution Channel

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2021

            14.5.2.1. By Therapy

            14.5.2.2. By Surgery

            14.5.2.3. By Distribution Channel

    14.6. U.K.

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2021

            14.6.2.1. By Therapy

            14.6.2.2. By Surgery

            14.6.2.3. By Distribution Channel

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2021

            14.7.2.1. By Therapy

            14.7.2.2. By Surgery

            14.7.2.3. By Distribution Channel

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2021

            14.8.2.1. By Therapy

            14.8.2.2. By Surgery

            14.8.2.3. By Distribution Channel

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2021

            14.9.2.1. By Therapy

            14.9.2.2. By Surgery

            14.9.2.3. By Distribution Channel

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2021

            14.10.2.1. By Therapy

            14.10.2.2. By Surgery

            14.10.2.3. By Distribution Channel

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2021

            14.11.2.1. By Therapy

            14.11.2.2. By Surgery

            14.11.2.3. By Distribution Channel

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2021

            14.12.2.1. By Therapy

            14.12.2.2. By Surgery

            14.12.2.3. By Distribution Channel

    14.13. GCC Countries

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2021

            14.13.2.1. By Therapy

            14.13.2.2. By Surgery

            14.13.2.3. By Distribution Channel

    14.14. South Africa

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2021

            14.14.2.1. By Therapy

            14.14.2.2. By Surgery

            14.14.2.3. By Distribution Channel

    14.15. Israel

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2021

            14.15.2.1. By Therapy

            14.15.2.2. By Surgery

            14.15.2.3. By Distribution Channel

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Therapy

        15.3.3. By Surgery

        15.3.4. By Distribution Channel

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. GlaxoSmithKline plc

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. Merck & Co., Inc.

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. F. Hoffmann-La Roche Ltd.

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Isis Pharmaceuticals, Inc.

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Eli Lilly and Company

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Novartis AG

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. Sanofi

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. Johnson and Johnson

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. Bayer AG

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. Cardium

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

        16.1.11. Pfizer Inc.

            16.1.11.1. Overview

            16.1.11.2. Product Portfolio

            16.1.11.3. Profitability by Market Segments

            16.1.11.4. Sales Footprint

            16.1.11.5. Strategy Overview

                16.1.11.5.1. Marketing Strategy

        16.1.12. AstraZeneca

            16.1.12.1. Overview

            16.1.12.2. Product Portfolio

            16.1.12.3. Profitability by Market Segments

            16.1.12.4. Sales Footprint

            16.1.12.5. Strategy Overview

                16.1.12.5.1. Marketing Strategy

        16.1.13. Amgen Inc.

            16.1.13.1. Overview

            16.1.13.2. Product Portfolio

            16.1.13.3. Profitability by Market Segments

            16.1.13.4. Sales Footprint

            16.1.13.5. Strategy Overview

                16.1.13.5.1. Marketing Strategy

        16.1.14. Mylan N.V.

            16.1.14.1. Overview

            16.1.14.2. Product Portfolio

            16.1.14.3. Profitability by Market Segments

            16.1.14.4. Sales Footprint

            16.1.14.5. Strategy Overview

                16.1.14.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Market Value (US$ Mn) Forecast by Region, 2016-2032

Table 02: Global Market Value (US$ Mn) Forecast by Therapy, 2016-2032

Table 03: Global Market Value (US$ Mn) Forecast by Surgery, 2016-2032

Table 04: Global Market Value (US$ Mn) Forecast by Distribution Channel, 2016-2032

Table 05: North America Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 06: North America Market Value (US$ Mn) Forecast by Therapy, 2016-2032

Table 07: North America Market Value (US$ Mn) Forecast by Surgery, 2016-2032

Table 08: North America Market Value (US$ Mn) Forecast by Distribution Channel, 2016-2032

Table 09: Latin America Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 10: Latin America Market Value (US$ Mn) Forecast by Therapy, 2016-2032

Table 11: Latin America Market Value (US$ Mn) Forecast by Surgery, 2016-2032

Table 12: Latin America Market Value (US$ Mn) Forecast by Distribution Channel, 2016-2032

Table 13: Europe Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 14: Europe Market Value (US$ Mn) Forecast by Therapy, 2016-2032

Table 15: Europe Market Value (US$ Mn) Forecast by Surgery, 2016-2032

Table 16: Europe Market Value (US$ Mn) Forecast by Distribution Channel, 2016-2032

Table 17: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 18: Asia Pacific Market Value (US$ Mn) Forecast by Therapy, 2016-2032

Table 19: Asia Pacific Market Value (US$ Mn) Forecast by Surgery, 2016-2032

Table 20: Asia Pacific Market Value (US$ Mn) Forecast by Distribution Channel, 2016-2032

Table 21: MEA Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 22: MEA Market Value (US$ Mn) Forecast by Therapy, 2016-2032

Table 23: MEA Market Value (US$ Mn) Forecast by Surgery, 2016-2032

Table 24: MEA Market Value (US$ Mn) Forecast by Distribution Channel, 2016-2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Market Value (US$ Mn) by Therapy, 2022-2032

Figure 02: Global Market Value (US$ Mn) by Surgery, 2022-2032

Figure 03: Global Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 04: Global Market Value (US$ Mn) by Region, 2022-2032

Figure 05: Global Market Value (US$ Mn) Analysis by Region, 2016-2032

Figure 06: Global Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 07: Global Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 08: Global Market Value (US$ Mn) Analysis by Therapy, 2016-2032

Figure 09: Global Market Value Share (%) and BPS Analysis by Therapy, 2022-2032

Figure 10: Global Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032

Figure 11: Global Market Value (US$ Mn) Analysis by Surgery, 2016-2032

Figure 12: Global Market Value Share (%) and BPS Analysis by Surgery, 2022-2032

Figure 13: Global Market Y-o-Y Growth (%) Projections by Surgery, 2022-2032

Figure 14: Global Market Value (US$ Mn) Analysis by Distribution Channel, 2016-2032

Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 17: Global Market Attractiveness by Therapy, 2022-2032

Figure 18: Global Market Attractiveness by Surgery, 2022-2032

Figure 19: Global Market Attractiveness by Distribution Channel, 2022-2032

Figure 20: Global Market Attractiveness by Region, 2022-2032

Figure 21: North America Market Value (US$ Mn) by Therapy, 2022-2032

Figure 22: North America Market Value (US$ Mn) by Surgery, 2022-2032

Figure 23: North America Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 24: North America Market Value (US$ Mn) by Country, 2022-2032

Figure 25: North America Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 28: North America Market Value (US$ Mn) Analysis by Therapy, 2016-2032

Figure 29: North America Market Value Share (%) and BPS Analysis by Therapy, 2022-2032

Figure 30: North America Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032

Figure 31: North America Market Value (US$ Mn) Analysis by Surgery, 2016-2032

Figure 32: North America Market Value Share (%) and BPS Analysis by Surgery, 2022-2032

Figure 33: North America Market Y-o-Y Growth (%) Projections by Surgery, 2022-2032

Figure 34: North America Market Value (US$ Mn) Analysis by Distribution Channel, 2016-2032

Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 37: North America Market Attractiveness by Therapy, 2022-2032

Figure 38: North America Market Attractiveness by Surgery, 2022-2032

Figure 39: North America Market Attractiveness by Distribution Channel, 2022-2032

Figure 40: North America Market Attractiveness by Country, 2022-2032

Figure 41: Latin America Market Value (US$ Mn) by Therapy, 2022-2032

Figure 42: Latin America Market Value (US$ Mn) by Surgery, 2022-2032

Figure 43: Latin America Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 44: Latin America Market Value (US$ Mn) by Country, 2022-2032

Figure 45: Latin America Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 48: Latin America Market Value (US$ Mn) Analysis by Therapy, 2016-2032

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Therapy, 2022-2032

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032

Figure 51: Latin America Market Value (US$ Mn) Analysis by Surgery, 2016-2032

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Surgery, 2022-2032

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Surgery, 2022-2032

Figure 54: Latin America Market Value (US$ Mn) Analysis by Distribution Channel, 2016-2032

Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 57: Latin America Market Attractiveness by Therapy, 2022-2032

Figure 58: Latin America Market Attractiveness by Surgery, 2022-2032

Figure 59: Latin America Market Attractiveness by Distribution Channel, 2022-2032

Figure 60: Latin America Market Attractiveness by Country, 2022-2032

Figure 61: Europe Market Value (US$ Mn) by Therapy, 2022-2032

Figure 62: Europe Market Value (US$ Mn) by Surgery, 2022-2032

Figure 63: Europe Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 64: Europe Market Value (US$ Mn) by Country, 2022-2032

Figure 65: Europe Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 68: Europe Market Value (US$ Mn) Analysis by Therapy, 2016-2032

Figure 69: Europe Market Value Share (%) and BPS Analysis by Therapy, 2022-2032

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032

Figure 71: Europe Market Value (US$ Mn) Analysis by Surgery, 2016-2032

Figure 72: Europe Market Value Share (%) and BPS Analysis by Surgery, 2022-2032

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Surgery, 2022-2032

Figure 74: Europe Market Value (US$ Mn) Analysis by Distribution Channel, 2016-2032

Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 77: Europe Market Attractiveness by Therapy, 2022-2032

Figure 78: Europe Market Attractiveness by Surgery, 2022-2032

Figure 79: Europe Market Attractiveness by Distribution Channel, 2022-2032

Figure 80: Europe Market Attractiveness by Country, 2022-2032

Figure 81: Asia Pacific Market Value (US$ Mn) by Therapy, 2022-2032

Figure 82: Asia Pacific Market Value (US$ Mn) by Surgery, 2022-2032

Figure 83: Asia Pacific Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 84: Asia Pacific Market Value (US$ Mn) by Country, 2022-2032

Figure 85: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 88: Asia Pacific Market Value (US$ Mn) Analysis by Therapy, 2016-2032

Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Therapy, 2022-2032

Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032

Figure 91: Asia Pacific Market Value (US$ Mn) Analysis by Surgery, 2016-2032

Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Surgery, 2022-2032

Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Surgery, 2022-2032

Figure 94: Asia Pacific Market Value (US$ Mn) Analysis by Distribution Channel, 2016-2032

Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 97: Asia Pacific Market Attractiveness by Therapy, 2022-2032

Figure 98: Asia Pacific Market Attractiveness by Surgery, 2022-2032

Figure 99: Asia Pacific Market Attractiveness by Distribution Channel, 2022-2032

Figure 100: Asia Pacific Market Attractiveness by Country, 2022-2032

Figure 101: MEA Market Value (US$ Mn) by Therapy, 2022-2032

Figure 102: MEA Market Value (US$ Mn) by Surgery, 2022-2032

Figure 103: MEA Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 104: MEA Market Value (US$ Mn) by Country, 2022-2032

Figure 105: MEA Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 106: MEA Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 107: MEA Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 108: MEA Market Value (US$ Mn) Analysis by Therapy, 2016-2032

Figure 109: MEA Market Value Share (%) and BPS Analysis by Therapy, 2022-2032

Figure 110: MEA Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032

Figure 111: MEA Market Value (US$ Mn) Analysis by Surgery, 2016-2032

Figure 112: MEA Market Value Share (%) and BPS Analysis by Surgery, 2022-2032

Figure 113: MEA Market Y-o-Y Growth (%) Projections by Surgery, 2022-2032

Figure 114: MEA Market Value (US$ Mn) Analysis by Distribution Channel, 2016-2032

Figure 115: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 116: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 117: MEA Market Attractiveness by Therapy, 2022-2032

Figure 118: MEA Market Attractiveness by Surgery, 2022-2032

Figure 119: MEA Market Attractiveness by Distribution Channel, 2022-2032

Figure 120: MEA Market Attractiveness by Country, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Heart Beat Irregularity Detection Device Market

Published : March 2022

Healthcare

Heart Failure Testing Market

Published : September 2019

Healthcare

Cholesterol Medicine Market

Published : January 2017

Healthcare

Coronary Artery Bypass Grafts Market

Published : March 2022

Google translate

Atherosclerosis Market